Watch Cleo’s Head of Corporate Development, Dayna Louca’s Q&A on the JMM Expert Insights Series

Cleo’s Chief Scientific Officer Dr Andrew Stephens and Head of Corporate Development Dayna Louca recently spoke at the JMM Opera House Investor Lunch on how their breakthrough CXCL10 biomarker platform could address one of medicine’s toughest challenges, the early detection of ovarian cancer.

Watch the Q&A with Head of Corporate Development Dayna Louca.

Andrew ZAPPIA 30/10/25 Andrew ZAPPIA 30/10/25

Cleo Diagnostics Clears Key Regulatory Hurdle with Stage One MDSAP Audit Success

Article by TechInvest

Cleo Diagnostics (ASX: COV) has reached a major regulatory milestone, announcing the successful completion of Stage One of the Medical Device Single Audit Program, or MDSAP. This marks a significant step toward global market access for its pre-surgical ovarian cancer diagnostic test.

Andrew ZAPPIA 2/5/25 Andrew ZAPPIA 2/5/25

Cleo Diagnostics' Big Strides Against Ovarian Cancer

Cleo Diagnostics Chief Scientific Officer, Dr Andrew Stephens, joins Andrew Geoghegan of ausbiz to discuss the importance of the partnership with the University College London to access 2000 UKCTOCS biobank samples.